Dundee – Confidence in Concept 2019
Lead Research Organisation:
University of Dundee
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
People |
ORCID iD |
Publications
Armstrong LA
(2021)
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies.
in PloS one
Pearson LA
(2021)
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
in SLAS discovery : advancing life sciences R & D
| Description | COVID-19 Lead Optimisation of New Broad-Spectrum Drug Candidate |
| Amount | £4,871,348 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 04/2021 |
| End | 05/2023 |
| Description | Callaboration with Bukwang - second program |
| Organisation | Bukwang Pharmaceutical |
| Country | Korea, Republic of |
| Sector | Private |
| PI Contribution | Provided the primary biology that allowed hit discovery for a new drug discovery project |
| Collaborator Contribution | Funding and route to clinical trials if successful |
| Impact | none so far |
| Start Year | 2021 |
| Description | Collaboration with Beactica |
| Organisation | Beactica |
| Country | Sweden |
| Sector | Private |
| PI Contribution | We have contributed platform technology and detailed knowledge of the target and associated chemical matter |
| Collaborator Contribution | Beactica have contributed key biophysical expertise that is enabling for the projects concerned |
| Impact | Multi-disciplinary - chemistry, biology, biophysical and computational methods |
| Start Year | 2021 |
| Description | Partnership with Exeed |
| Organisation | Epidarex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discovery of small molecule inhibitors of a methyltransferase - patent on structural platform |
| Collaborator Contribution | Funding and scientific input into aligning the pharmacological profile with a commercial disease indication |
| Impact | none as yet |
| Start Year | 2021 |